Comparative Pharmacology
Head-to-head clinical analysis: FLUTEX versus PSORCON E.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUTEX versus PSORCON E.
FLUTEX vs PSORCON E
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Flutamide is a nonsteroidal antiandrogen that competitively inhibits the binding of dihydrotestosterone (DHT) to androgen receptors in target tissues, thereby blocking the androgenic effects.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to produce anti-inflammatory, antipruritic, and vasoconstrictive effects.
50 mg orally once daily
Topical: Apply a thin film to affected skin areas twice daily. No systemic dosing applicable.
None Documented
None Documented
Terminal elimination half-life: 24–36 hours, permitting once-daily dosing in chronic therapy
Terminal elimination half-life is approximately 6-8 hours for the parent compound; active metabolites may have half-lives up to 12 hours. Clinically, this supports twice-daily dosing.
Renal: ~70% (50% unchanged, 20% as metabolites); Biliary/fecal: ~30%
Primarily hepatic metabolism followed by renal excretion of metabolites; less than 5% excreted unchanged in urine. Biliary/fecal elimination accounts for <2%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid